Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.52 |
| ▸ | S100A10 | P60903 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197138 | 0.84 | HTT (0.68) | HTTPOLBLMNAMAPTALDH1A1 | |
| SCHEMBL17896872 | 0.81 | HTT (0.71) | HTTLMNAMAPTANXA2S100A10 | |
| Nefiracetam SCHEMBL135856 | 0.77 | HTT (0.66) | HTTPOLBLMNAMAPTKDM4E | |
| SCHEMBL24177661 | 0.76 | HTT (0.60) | HTTPOLBLMNATP53RAB9A | |
| SCHEMBL24177662 | 0.74 | HTT (0.54) | HTTPOLBLMNATP53RAB9A | |
| SCHEMBL7437681 | 0.74 | HTT (0.60) | HTTPOLBLMNAALDH1A1 | |
| SCHEMBL2009980 | 0.74 | MEN1 (0.72) | HTTPOLBLMNAALDH1A1 | |
| SCHEMBL11391291 | 0.74 | HTT (1.00) | HTTLMNAMAPTTP53RAB9A | |
| SCHEMBL11570308 | 0.72 | LMNA (0.56) | HTTLMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL4191223 | 0.72 | ALDH1A1 (0.60) | HTTMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173945-A1 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2010-07-08 | — | — | US | disclosed |
| EP-1608655-B8 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | BRANE DISCOVERY SRL IN LIQUIDA (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1608655-B1 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH SRL (IT) | 2008-07-16 | — | — | EP | disclosed |
| EP-1608655-A2 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085438-A2 | PYRROLOIMIDAZOLE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND THEIR USE AS NOOTROPIC AGENTS | NIKEM RESEARCH S.R.L. (IT) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173945-A1 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | GRIN3B, GRIN3A, GRIN1 | HTT 762/4885POLB 4750/4885LMNA 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.